Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7459.51 | 1445 / 1445 | 99% | 3.60 | 181 / 183 |
stomach | 100% | 5263.91 | 359 / 359 | 86% | 2.37 | 247 / 286 |
ovary | 100% | 4868.94 | 180 / 180 | 86% | 2.06 | 368 / 430 |
lung | 100% | 6926.10 | 578 / 578 | 85% | 2.10 | 978 / 1155 |
intestine | 100% | 7002.60 | 966 / 966 | 76% | 1.73 | 399 / 527 |
breast | 100% | 6147.22 | 459 / 459 | 73% | 1.55 | 818 / 1118 |
brain | 100% | 6103.34 | 2640 / 2642 | 70% | 1.20 | 495 / 705 |
pancreas | 100% | 4215.00 | 328 / 328 | 70% | 1.32 | 124 / 178 |
bladder | 100% | 6345.71 | 21 / 21 | 69% | 1.62 | 348 / 504 |
skin | 100% | 8098.34 | 1809 / 1809 | 63% | 1.10 | 295 / 472 |
thymus | 100% | 5969.95 | 653 / 653 | 59% | 0.94 | 354 / 605 |
uterus | 100% | 5557.95 | 170 / 170 | 57% | 1.02 | 261 / 459 |
kidney | 100% | 6318.47 | 89 / 89 | 49% | 0.96 | 444 / 901 |
prostate | 100% | 6763.65 | 245 / 245 | 48% | 0.76 | 240 / 502 |
adrenal gland | 100% | 6262.41 | 258 / 258 | 22% | 0.31 | 51 / 230 |
liver | 100% | 3407.61 | 226 / 226 | 10% | 0.14 | 39 / 406 |
adipose | 100% | 6831.02 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5776.57 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 4827.04 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 6629.10 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 5401.55 | 928 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 4818.02 | 851 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 0.96 | 16 / 29 |
tonsil | 0% | 0 | 0 / 0 | 40% | 0.57 | 18 / 45 |
eye | 0% | 0 | 0 / 0 | 30% | 0.44 | 24 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0000209 | Biological process | protein polyubiquitination |
GO_1902523 | Biological process | positive regulation of protein K63-linked ubiquitination |
GO_0006282 | Biological process | regulation of DNA repair |
GO_1902533 | Biological process | positive regulation of intracellular signal transduction |
GO_0006301 | Biological process | postreplication repair |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0030154 | Biological process | cell differentiation |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0031371 | Cellular component | ubiquitin conjugating enzyme complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0031372 | Cellular component | UBC13-MMS2 complex |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | UBE2V1 |
Protein name | HCG2018358, isoform CRA_d (Ubiquitin conjugating enzyme E2 V1) Ubiquitin-conjugating enzyme E2 variant 1 (UEV-1) (CROC-1) (TRAF6-regulated IKK activator 1 beta Uev1A) Ubiquitin-conjugating enzyme E2 variant 1 |
Synonyms | P/OKcl.19 CROC1 UBE2V UEV1 hCG_2018358 |
Description | FUNCTION: Has no ubiquitin ligase activity on its own. The UBE2V1-UBE2N heterodimer catalyzes the synthesis of non-canonical poly-ubiquitin chains that are linked through Lys-63. This type of poly-ubiquitination activates IKK and does not seem to involve protein degradation by the proteasome. Plays a role in the activation of NF-kappa-B mediated by IL1B, TNF, TRAF6 and TRAF2. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. Together with RNF135 and UBE2N, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production . UBE2V1-UBE2N together with TRAF3IP2 E3 ubiquitin ligase mediate 'Lys-63'-linked polyubiquitination of TRAF6, a component of IL17A-mediated signaling pathway. . |
Accessions | ENST00000557021.5 G3V2F7 ENST00000371677.7 [Q13404-7] ENST00000371674.8 [Q13404-4] ENST00000617119.4 ENST00000371657.9 [Q13404-8] ENST00000483534.5 ENST00000625172.3 ENST00000340309.7 [Q13404-7] ENST00000415862.6 [Q13404-6] D6RG00 Q13404 |